On 21 June 2024 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation on the legitimacy of granting approval for the reimbursement of S.O.S. 10, S.O.S. 15, S.O.S. 20, S.O.S. 25 products in the indication: Dietary supplementation in the correct balancing of daily energy requirements and stabilization in the course of propionic aciduria, glutaric aciduria, aciduria Methylmalonic aciduria, primary hyperammonemia, LCHADD deficiency, VLCA deficiency, lysinuric protein intolerance, glycogenosis, maple syrup disease, CPS1 deficiency Translated with DeepL.com (free version)